Sökning: "PK PD"

Visar resultat 1 - 5 av 30 avhandlingar innehållade orden PK PD.

1. 1. Pharmacometric Models for Antibacterial Agents to Improve Dosing Strategies

   Författare :Elisabet I Nielsen; Lena E Friberg; Otto Cars; Mats O Karlsson; Marie Sandström; Alan Forrest; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; pharmacokinetics; pharmacodynamics; modeling; NONMEM; antibiotics; in vitro; time-kill curve; PK PD indices; gentamicin; aminoglycosides; newborn infants; premature infants; cystatin C; Biopharmacy; Biofarmaci; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

   Sammanfattning : Antibiotics are among the most commonly prescribed drugs. Although the majority of these drugs were developed several decades ago, optimal dosage (dose, dosing interval and treatment duration) have still not been well defined. LÄS MER

3. 2. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants

   Författare :Anna Karin Belfrage; Anja Sandström; Ulf Ellervik; Uppsala universitet; []
   Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; hepatitis C virus; HCV; NS3 protease inhibitors; structure-activity relationship; 2 1H -pyrazinone; quinazoline; resistance; Pd catalysis; Medicinal Chemistry; Läkemedelskemi; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. LÄS MER

4. 3. Physiologically Based Pharmacometric Models for Colistin and the Immune Response to Bacterial Infection

   Författare :Salim Bouchene; Mats O. Karlsson; Wilhelm Huisinga; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; PBPK model; endotoxin; colistin; WBPBPK-PD; CMS; inflammation; tissue distribution; Kp; predictions in tissue; interspecies scaling;

   Sammanfattning : Antibiotic treatment failure might be due to bacterial resistance or suboptimal exposure at target site and there is a lack of knowledge on the interaction between antimicrobial pharmacodynamics (PD) and the immune response to bacterial infections. Therefore, it is crucial to develop tools to increase the understanding of drug disposition to better evaluate antibiotic candidates in drug development and to elucidate the role of the immune system in bacterial infections. LÄS MER

5. 4. Safety and Efficacy Modelling in Anti-Diabetic Drug Development

   Författare :Bengt Hamrén; Mats O Karlsson; Eric Snoeck; Uppsala universitet; []
   Nyckelord :Pharmaceutical biosciences; pharmacokinetic; pharmacodynamic; mechanism-based; modelling; type 2 diabetes mellitus; tesaglitazar; PPAR; drug development; NONMEM; Farmaceutisk biovetenskap;

   Sammanfattning : A central aim in drug development is to ensure that the new drug is efficacious and safe in the intended patient population. Mathematical models describing the pharmacokinetic-pharmacodynamic (PK-PD) properties of a drug are valuable to increase the knowledge about drug effects and disease and can be used to inform decisions. LÄS MER

7. 5. Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel

   Författare :Anja Henningsson; Mats O. Karlsson; Lena Friberg; Iñaki F. Trocóniz; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Pharmacokinetics; Pharmacodynamics; Mechanism-based; Modelling; Myelosuppression; Paclitaxel; Cremophor EL; NONMEM; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI;

   Sammanfattning : Paclitaxel (Taxol®) is now widely used against breast, ovarian and non-small-cell lung cancer. Anticancer agents generally have narrow therapeutic indices, often with myelosuppression (mainly neutropenia) as dose-limiting side effect. LÄS MER